This page in Swedish

Carl Eriksson

Position: Adjunct Senior Lecturer School/office: School of Medical Sciences

Email: Y2FybC5lcmlrc3NvbjtvcnUuc2U=

Phone: No number available

Room: -

Research subject

Medicine

About Carl Eriksson

I am an Associate Professor (Docent) in Medical Science, Adjunct Senior Lecturer at Örebro University, and Senior Consultant in Gastroenterology and Hepatology at Örebro University Hospital. My clinical work and research primarily focus on inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis.

I received my PhD from Örebro University in 2018 and subsequently completed a postdoctoral fellowship in clinical epidemiology at Karolinska Institutet.

Research
My research focuses on inflammatory bowel disease, with a particular emphasis on clinical epidemiology. I use Swedish national health registers and quality registers to study why IBD develops, how the disease progresses over time, and how different treatments affect disease course and complications.

One current area of research is the role of early-life environmental factors in the risk of developing IBD. Using Swedish twin, birth, and adoption registers, we investigate the relative contributions of genetic and environmental factors. The aim is to better understand the causes of IBD and to identify factors that can predict disease course and complications.

Teaching
I teach at the medical programme at Örebro University and am responsible for the subject area of Gastroenterology and Hepatology. I also supervise students and PhD students in clinical gastroenterology and epidemiological research.

Active projects

Research groups

Inflammatory bowel disease and translational gastroenterology

Publications

Articles in journals

Bröms, G. , Forss, A. , Eriksson, J. , Askling, J. , Eriksson, C. , Halfvarson, J. , Linder, M. , Sun, J. & et al. (2025). Adult-onset inflammatory bowel disease and the risk of venous thromboembolism: a Swedish nationwide cohort study 2007-2021. Scandinavian Journal of Gastroenterology, 60 (6), 526-535. [BibTeX]
Pertsinidou, E. , Salomon, B. , Bergemalm, D. , Salihovic, S. , Hedin, C. R. H. , Ling Lundström, M. , Keita, Å. V. , Magnusson, M. K. & et al. (2025). Anti-integrin αvβ6 IgG antibody as a diagnostic and prognostic marker in ulcerative colitis: A cross-sectional and longitudinal study defining a specific disease phenotype. Journal of Crohn's & Colitis, 19 (5). [BibTeX]
Salomon, B. , Grännö, O. , Bergemalm, D. , Strid, H. , Carstens, A. , Hjortswang, H. , Lundström, M. L. , Hreinsson, J. P. & et al. (2025). Cohort profile: the Swedish Inception Cohort in inflammatory bowel disease (SIC-IBD). BMJ Open, 15 (5). [BibTeX]
Ryen, L. , Visuri, I. , Karlqvist, S. , Malmgren, C. , Bergemalm, D. & Eriksson, C. (2025). Healthcare resource utilization and production loss in vedolizumab-treated inflammatory bowel disease patients: results from the Swedish prospective multicentre SVEAH study. Therapeutic Advances in Gastroenterology, 18. [BibTeX]
Forss, A. , Bröms, G. , Bergman, D. , Thuresson, M. , Sun, J. , Eriksson, C. , Olén, O. , Zöller, B. & et al. (2025). Microscopic colitis and risk of venous thromboembolism: A nationwide matched cohort study. American Journal of Gastroenterology, 120 (12), 2867-2876. [BibTeX]
Stenberg, E. , Everhov, Å. H. , Söderling, J. , Ottosson, J. , Osooli, M. , Andersson, E. , Bergemalm, D. , Ludvigsson, J. F. & et al. (2025). Outcomes of inflammatory bowel disease in patients with obesity following bariatric surgery: propensity score-matched cohort study. BJS Open, 9 (4). [BibTeX]
Grännö, O. , Bergemalm, D. , Salomon, B. , Lindqvist, C. M. , Hedin, C. R. H. , Carlson, M. , Dannenberg, K. , Andersson, E. & et al. (2025). Preclinical protein signatures of Crohn's disease and ulcerative colitis: A nested case-control study within large population-based cohorts. Gastroenterology, 168 (4), 741-753. [BibTeX]
Karlqvist, S. , Sachs, M. C. , Eriksson, C. , Cao, Y. , Montgomery, S. , Ludvigsson, J. F. , Olén, O. & Halfvarson, J. (2025). Response to Dai et al. American Journal of Gastroenterology, 120 (1), 260-261. [BibTeX]
Khalili, H. , Forss, A. , Söderling, J. , Bröms, G. , Eriksson, C. , Sun, J. , Ludvigsson, J. F. & Olén, O. (2025). Statin Use is Associated with a Less Severe Disease Course In Inflammatory Bowel Disease: A Nationwide Cohort Study 2006-2020. Inflammatory Bowel Diseases, 31 (10), 2787-2797. [BibTeX]
Karlqvist, S. , Sachs, M. C. , Eriksson, C. , Cao, Y. , Montgomery, S. , Ludvigsson, J. F. , Olén, O. , Halfvarson, J. & et al. (2024). Comparative Risk of Serious Infection With Vedolizumab vs Anti-Tumor Necrosis Factor in Inflammatory Bowel Disease: Results From Nationwide Swedish Registers. American Journal of Gastroenterology, 119 (2), 2480-2492. [BibTeX]
Thunberg, J. , Grännö, O. , Bergemalm, D. , Eriksson, C. , Visuri, I. , Eberhardson, M. & Halfvarson, J. (2024). Comparative study of a point-of-care test and an enzyme-linked immunosorbent assay (ELISA) for infliximab levels. Scandinavian Journal of Gastroenterology, 59 (2), 150-155. [BibTeX]
Eriksson, C. , Sun, J. , Bryder, M. , Bröms, G. , Everhov, Å. H. , Forss, A. , Jernberg, T. , Ludvigsson, J. F. & et al. (2024). Impact of inflammatory bowel disease on the risk of acute coronary syndrome: A Swedish Nationwide Cohort Study. Alimentary Pharmacology and Therapeutics, 59 (9), 1122-1133. [BibTeX]
Lamichhane, N. , Melas, N. , Bergqvist, V. , Ekholm, N. , Olén, O. , Ludvigsson, J. F. , Hjortswang, H. , Marsal, J. & et al. (2024). Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease. Digestive Diseases and Sciences, 69 (6), 2175-2183. [BibTeX]
Shrestha, S. , Brand, J. S. , Osooli, M. , Eriksson, C. , Schoultz, I. , Askling, J. , Jess, T. , Montgomery, S. & et al. (2024). Spondyloarthritis in first-degree relatives and spouses of patients with inflammatory bowel disease: A nationwide population-based cohort study from Sweden. Journal of Crohn's & Colitis, 18 (9), 1371-1380. [BibTeX]
Visuri, I. , Eriksson, C. , Karlqvist, S. , Lykiardopoulos, B. , Karlén, P. , Grip, O. , Söderman, C. , Almer, S. & et al. (2023). Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study. Therapeutic Advances in Gastroenterology, 16. [BibTeX]
Wallhuss, A. , Ottosson, J. , Cao, Y. , Andersson, E. , Bergemalm, D. , Eriksson, C. , Olén, O. , Szabo, E. & et al. (2023). Outcomes of bariatric surgery for patients with prevalent inflammatory bowel disease: A nationwide registry-based cohort study. Surgery, 174 (2), 144-151. [BibTeX]
Eriksson, C. , Söderling, J. , Karlqvist, S. , Bröms, G. , Everhov, Å. H. , Bergemalm, D. , Ludvigsson, J. F. , Olén, O. & et al. (2023). Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease. Digestive Diseases and Sciences, 68 (7), 3119-3128. [BibTeX]
Yanai, H. , Eriksson, C. & Aharoni Golan, M. (2022). Endoscopic Postoperative Recurrence In Crohn's Disease After Curative Ileocecal Resection With Early Prophylaxis By Anti-Tnf, Vedolizumab Or Ustekinumab: A Real-World Multicenter European Study. Journal of Crohn's & Colitis, 16 (12), 1882-1892. [BibTeX]
Phillips, F. , Verstockt, B. , Sladek, M. , de Boer, N. , Katsanos, K. , Karmiris, K. , Albshesh, A. , Erikson, C. & et al. (2022). Orofacial Granulomatosis associated with Crohn's Disease: a multi-centre case series. Journal of Crohn's & Colitis, 16 (3), 430-435. [BibTeX]
Thunberg, J. , Björkqvist, O. , Hedin, C. R. H. , Forss, A. , Söderman, C. , Bergemalm, D. , Olén, O. , Hjortswang, H. & et al. (2022). Ustekinumab treatment in ulcerative colitis: Real-world data from the Swedish inflammatory bowel disease quality register. United European Gastroenterology journal, 10 (7), 631-639. [BibTeX]
Eriksson, C. , Visuri, I. , Vigren, L. , Nilsson, L. , Kärnell, A. , Hjortswang, H. , Bergemalm, D. , Almer, S. & et al. (2021). Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG. Scandinavian Journal of Gastroenterology, 56 (11), 1304-1311. [BibTeX]
Rundquist, S. , Sachs, M. C. , Eriksson, C. , Olén, O. , Montgomery, S. & Halfvarson, J. (2021). Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers. Alimentary Pharmacology and Therapeutics, 53 (4), 471-483. [BibTeX]
Rundquist, S. , Sachs, M. C. , Eriksson, C. , Olén, O. , Montgomery, S. & Halfvarson, J. (2021). Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game-authors' reply. Alimentary Pharmacology and Therapeutics, 53 (5), 642-643. [BibTeX]
Albshesh, A. , Taylor, J. , Savarino, E. V. , Truyens, M. , Armuzzi, A. , Ribaldone, D. G. , Shitrit, A. B. , Fibelman, M. & et al. (2021). Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study. Journal of Clinical Medicine, 10 (13). [BibTeX]
Rundquist, S. , Sachs, M. C. , Eriksson, C. , Olén, O. , Montgomery, S. & Halfvarson, J. (2021). Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD. Authors' reply. Alimentary Pharmacology and Therapeutics, 53 (9), 1046-1047. [BibTeX]
Visuri, I. , Eriksson, C. , Olén, O. , Cao, Y. , Mårdberg, E. , Grip, O. , Gustavsson, A. , Hjortswang, H. & et al. (2021). Predictors of drug survival: A cohort study comparing anti-tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register. Alimentary Pharmacology and Therapeutics, 54 (7), 931-943. [BibTeX]
Eriksson, C. , Rundquist, S. , Lykiardopoulos, V. , Udumyan, R. , Karlén, P. , Grip, O. , Söderman, C. , Almer, S. & et al. (2021). Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study. Therapeutic Advances in Gastroenterology, 14. [BibTeX]
Bergemalm, D. , Andersson, E. , Hultdin, J. , Eriksson, C. , Rush, S. T. , Kalla, R. , Adams, A. T. , Keita, Å. V. & et al. (2021). Systemic Inflammation in Preclinical Ulcerative Colitis. Gastroenterology, 161 (5), 1526-1539.e9. [BibTeX]
Wildeman, P. , Tevell, S. , Eriksson, C. , Lagos, A. C. , Söderquist, B. & Stenmark, B. (2020). Genomic characterization and outcome of prosthetic joint infections caused by Staphylococcus aureus. Scientific Reports, 10 (1). [BibTeX]
Burisch, J. , Eriksson, C. , Halfvarson, J. & Odes, S. (2020). Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study. The Lancet Gastroenterology & Hepatology, 5 (5), 454-464. [BibTeX]
Moens, A. , van der Woude, C. J. , Julsgaard, M. , Humblet, E. , Sheridan, J. , Baumgart, D. C. , De Saint-Joseph, C. G. , Nancey, S. & et al. (2020). Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. Alimentary Pharmacology and Therapeutics, 51 (1), 129-138. [BibTeX]
Shrestha, S. , Olén, O. , Eriksson, C. , Everhov, Å. H. , Myrelid, P. , Visuri, I. , Ludvigsson, J. F. , Schoultz, I. & et al. (2020). The use of ICD codes to identify IBD subtypes and phenotypes of the Montreal classification in the Swedish National Patient Register. Scandinavian Journal of Gastroenterology, 55 (4), 430-435. [BibTeX]
Burisch, J. , Chetcuti Zammit, S. , Ellul, P. , Turcan, S. , Duricova, D. , Bortlik, M. , Winther Andersen, K. , Andersen, V. & et al. (2019). Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort: an Epi-IBD study. Journal of Gastroenterology and Hepatology, 34 (6), 996-1003. [BibTeX]
Eriksson, C. , Rundquist, S. , Cao, Y. , Montgomery, S. & Halfvarson, J. (2019). Impact of thiopurines on the natural history and surgical outcome of ulcerative colitis: a cohort study. Gut, 68 (4), 623-632. [BibTeX]
Burisch, J. , Kiudelis, G. , Kupcinskas, L. , Kievit, H. A. L. , Andersen, K. W. , Andersen, V. , Salupere, R. , Pedersen, N. & et al. (2019). Natural disease course of Crohn's disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut, 68 (3), 423-433. [BibTeX]
Burisch, J. , Katsanos, K. H. , Christodoulou, D. K. , Barros, L. , Magro, F. , Pedersen, N. , Kjeldsen, J. , Vegh, Z. & et al. (2019). Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study. Journal of Crohn's & Colitis, 13 (2), 198-208. [BibTeX]
Rundquist, S. , Eriksson, C. , Nilsson, L. , Angelison, L. , Jäghult, S. , Björk, J. , Grip, O. , Hjortswang, H. & et al. (2018). Clinical effectiveness of golimumab in Crohn's disease: an observational study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). Scandinavian Journal of Gastroenterology, 53 (10-11), 1257-1263. [BibTeX]
Eriksson, C. , Henriksson, I. , Brus, O. , Zhulina, Y. , Nyhlin, N. , Tysk, C. , Montgomery, S. & Halfvarson, J. (2018). Incidence, prevalence and clinical outcome of anaemia in inflammatory bowel disease: a population-based cohort study. Alimentary Pharmacology and Therapeutics, 48 (6), 638-645. [BibTeX]
Eriksson, C. , Rundquist, S. , Lykiardopoulos, B. , Karlén, P. , Grip, O. , Söderman, C. , Almer, S. , Hertervig, E. & et al. (2017). A Swedish observational study (SVEAH) on vedolizumab assessing effectiveness and healthcare resource utilization in patients with inflammatory bowel disease. Journal of Crohn's & Colitis, 11 (Suppl. 1), S262-S263. [BibTeX]
Eriksson, C. , Cao, Y. , Rundquist, S. , Zhulina, Y. , Henriksson, I. , Montgomery, S. & Halfvarson, J. (2017). Changes in medical management and colectomy rates: a population-based cohort study on the epidemiology and natural history of ulcerative colitis in Orebro, Sweden, 1963-2010. Alimentary Pharmacology and Therapeutics, 46 (8), 748-757. [BibTeX]
Eriksson, C. , Cao, Y. , Rundquist, S. , Zhulina, Y. , Henriksson, I. , Montgomery, S. & Halfvarson, J. (2017). Editorial: do thiopurines and biologics decrease the risk of colectomy? Authors' reply. Alimentary Pharmacology and Therapeutics, 46 (9), 897-898. [BibTeX]
Eriksson, C. , Marsal, J. , Bergemalm, D. , Vigren, L. , Björk, J. , Eberhardson, M. , Karling, P. , Söderman, C. & et al. (2017). Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). Scandinavian Journal of Gastroenterology, 52 (6-7), 722-729. [BibTeX]

Articles, reviews/surveys

Eriksson, C. , Gustavsson, A. , Kronvall, T. & Tysk, C. (2011). Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature. Journal of Gastrointestinal and Liver Diseases, 20 (1), 77-80. [BibTeX]

Conference papers

Grännö, O. , Bergemalm, D. , Salomon, B. , Lindqvist, C. M. , Hedin, C. R. , Carlson, M. , Erik, A. , Strid, H. & et al. (2026). A protein signature for prediction of disease course in newly diagnosed Ulcerative Colitis. In: Journal of Crohn's & Colitis. Paper presented at 21st Congress of ECCO, Stockholm, Sweden, February 18-21, 2026. (pp. 17-20). Oxford University Press. [BibTeX]
Germanopoulos, A. , Bergemalm, D. , Grännö, O. , Salomon, B. , Eriksson, C. , Kruse, R. , Hedin, C. R. , Carlson, M. & et al. (2026). A proximity extension assay-based serum assay enabling absolute quantification of prognostic proteins in inflammatory bowel disease: Development and Analytical Validation. In: Journal of Crohn's & Colitis. Paper presented at 21st Congress of ECCO, Stockholm, Sweden, February 18-21, 2026. (pp. i915-i917). Oxford University Press. [BibTeX]
Eriksson, C. , Forss, A. , Singh, S. , Halfvarson, J. , Sun, J. , Söderling, J. , Everhov, A. H. , Bröms, G. & et al. (2026). Major adverse cardiovascular events in patients with IBD treated with different therapies: A nationwide cohort study 2007-2023. In: Journal of Crohn's & Colitis. Paper presented at 21st Congress of ECCO, Stockholm, Sweden, February 18-21, 2026. (pp. i2896-i2897). Oxford University Press. [BibTeX]
Salihovic, S. , Oyås, O. , Hyll Hansen, S. , Salomon, B. , Bergemalm, D. , Hjortswang, H. , Grännö, O. , Hedin, C. R. & et al. (2026). Non-targeted lipidomic profiling reveals distinct molecular signatures in inflammatory bowel disease: Discovery and validation in two inception cohorts. In: Journal of Crohn's & Colitis. Paper presented at 21st Congress of ECCO, Stockholm, Sweden, February 18-21, 2026. (pp. i1463-i1465). Oxford University Press. [BibTeX]
Pertsinidou, E. , Grännö, O. , Bergemalm, D. , Salomon, B. , Salihovic, S. , Eriksson, C. , Lindqvist, C. M. , Moverare, R. & et al. (2026). Preclinical Anti-Integrin αvβ6 Autoantibodies in Ulcerative Colitis: Validation of Predictive Performance, Early Life Emergence and Environmental Modifiers across Multiple Population-Based Cohorts. In: Journal of Crohn's & Colitis. Paper presented at 21st Congress of ECCO, Stockholm, Sweden, February 18-21, 2026. (pp. i76-i78). Oxford University Press. [BibTeX]
Visuri, I. , Dannenberg, K. , Salomon, B. , Lundström, M. L. , Bergemalm, D. , Eriksson, C. , Lindqvist, M. , Keita, Å. V. & et al. (2025). Correlations of clinical characteristics and serum proteins with drug levels: A multicentre cohort study of patients with inflammatory bowel disease starting biologics. In: Journal of Crohn's & Colitis. Oxford University Press. [BibTeX]
Karlqvist, S. , Sachs, M. , Eriksson, C. , Cao, Y. , Montgomery, S. , Ludvigsson, J. F. , Olén, O. & Halfvarson, J. (2024). Comparative risk of serious infection with vedolizumab vs anti-TNF in Inflammatory Bowel Disease: Results from nationwide Swedish registers. In: Journal of Crohn's & Colitis. Paper presented at 19th Congress of ECCO, Stockholm, Sweden, February 21-24, 2024. (pp. I1291-I1293). Oxford University Press. [BibTeX]
Bröms, G. , Forss, A. , Eriksson, J. , Linder, M. , Eriksson, C. , Askling, J. , Halfvarson, J. , Ludvigsson, J. F. & et al. (2024). Disease characteristics at time of diagnosis of adult onset inflammatory bowel disease and the risk of venous thromboembolism in the modern era - A Swedish nationwide cohort study 2007-2021. In: Journal of Crohn's & Colitis. Paper presented at 19th Congress of ECCO, Stockholm, Sweden, February 21-24, 2024. (pp. I1945-I1947). Oxford University Press. [BibTeX]
Grännö, O. , Salomon, B. , Lindqvist, C. M. , Hedin, C. R. H. , Carlson, M. , Dannenberg, K. , Andersson, E. , Söderholm, J. D. & et al. (2024). Preclinical protein signatures in blood predict Crohn's disease and Ulcerative colitis several years before the diagnosis. In: Journal of Crohn's & Colitis. Paper presented at 9th Congress of ECCO, Stockholm, Sweden, February 21-24, 2024. (pp. I660-I661). Oxford University Press. [BibTeX]
Salomon, B. , Carlson, M. , Bergemalm, D. , Hedin, C. R. H. , Söderholm, J. D. , Keita, Å. V. , Carsten, A. , Grip, O. & et al. (2024). Prognostic potential of mucosal proteins in Ulcerative Colitis. In: Journal of Crohn's & Colitis. Paper presented at 16th Congress of ECCO - European Crohn’s and Colitis Organisation (ECCO'21), (Virtual congress), July 2-3, 8-10, 2021. (pp. I544-I545). Oxford University Press. [BibTeX]
Bazov, I. , Kruse, R. , Bergemalm, D. , Eriksson, C. , Hedin, C. R. , Carlson, M. , van Nieuwenhoven, M. , Keita, Å. V. & et al. (2023). A novel serum protein signature as biomarker for Inflammatory Bowel Disease: A diagnostic performance and prediction modelling study using data from two independent inception cohorts. In: Journal of Crohn's & Colitis. Paper presented at 18th Congress of ECCO Copenhagen, Denmark, March 1-4, 2023. (pp. I314-I315). Oxford University Press. [BibTeX]
Wewer, M. D. , Salupere, R. , Kievit, H. A. L. , Nielsen, K. R. , Midjord, J. , Domislovic, V. , Krznarić, Ž. , Pedersen, N. & et al. (2023). Disease course of Crohn's disease during the first ten years following diagnosis in a prospective European population-based inception cohort - the Epi-IBD cohort. In: Journal of Crohn's & Colitis. Oxford University Press. [BibTeX]
Wewer, M. D. , Salupere, R. , Kievit, H. A. L. , Nielsen, K. R. , Midjord, J. , Domislovic, V. , Krznarić, Ž. , Pedersen, N. & et al. (2023). Disease course of Ulcerative Colitis during the first ten years following diagnosis in a prospective European population-based inception cohort - the Epi-IBD cohort. In: Journal of Crohn's & Colitis. Paper presented at 18th Congress of ECCO, Copenhagen, Denmark, March 1-4, 2023. (pp. 994-995). Oxford University Press. [BibTeX]
Thunberg, J. , Björkqvist, O. , Olén, O. , Ludvigsson, J. F. , Eriksson, C. & Halfvarson, J. (2021). Drug survival and remission rates in ustekinumab treated ulcerative colitis: Results from the Swedish Inflammatory Bowel Disease register (SWIBREG). In: Journal of Crohn's & Colitis. Paper presented at 16th Congress of ECCO - European Crohn’s and Colitis Organisation (ECCO'21), (Virtual congress), July 2-3, 8-10, 2021. (pp. S317-S317). Oxford University Press. [BibTeX]
Rundquist, S. , Sachs, M. , Eriksson, C. , Olén, O. , Montgomery, S. & Halfvarson, J. (2020). Effectiveness of anti-TNF vs. vedolizumab as a second biologic in IBD: results from national Swedish registers. In: Journal of Crohn's & Colitis. Oxford University Press. [BibTeX]
Phillips, F. , Verstockt, B. , Sladek, M. , de Boer, N. , Katsanos, K. , Karmiris, K. , Albshesh, A. , Eriksson, C. & et al. (2020). Orofacial granulomatosis in Crohn's disease: an ECCO CONFER multi-centre case series. In: Journal of Crohn's & Colitis. Oxford University Press. [BibTeX]
Eriksson, C. , Rundquist, S. , Lykiardopoulos, V. , Udumyan, R. , Karlén, P. , Grip, O. , Söderman, C. , Almer, S. & et al. (2020). Real-world effectiveness of vedolizumab in ulcerative colitis: Week 52 results from the Swedish multi-centre, prospective, observational SVEAH UC study. In: Journal of Crohn's & Colitis. Oxford University Press. [BibTeX]
Visuri, I. , Eriksson, C. , Mårdberg, E. , Grip, O. , Gustavsson, A. , Hjortswang, H. , Karling, P. , Montgomery, S. & et al. (2019). Anti-TNF agent drug survival in patients with IBD: real-world comparisons of individual anti-TNF agents based on the Swedish National Quality Registry for IBD (SWIBREG). In: Journal of Crohn's & Colitis. Oxford University Press. [BibTeX]
Bergemalm, D. , Andersson, E. , Karling, P. , Eriksson, C. , Repsilber, D. , Hultdin, J. , Halfvarson, J. & IBD Character Consortium, . (2019). Markers of systemic inflammation in preclinical ulcerative colitis. In: United European Gastroenterology journal. Sage Publications. [BibTeX]
Moens, A. , van der Woude, C. , Julsgaard, M. , Sebastian, S. , Arebi, N. , Alzinaty, M. , Humblet, E. , Kok, K. B. & et al. (2019). Pregnancy outcomes in IBD patients treated with vedolizumab, anti-TNF, or conventional therapy. In: Journal of Crohn's & Colitis. Oxford University Press. [BibTeX]
Rundquist, S. , Eriksson, C. , Nilsson, L. , Angelison, L. , Jäghult, S. , Björk, J. , Grip, O. , Hjortswang, H. & et al. (2018). Clinical effectiveness of golimumab in Crohn´s disease – an observational study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). Paper presented at 26th United European Gastroenterology Week, Vienna, Austria, October 20-24, 2018. [BibTeX]
Eriksson, C. , Bergemalm, D. , Vigren, L. , Nilsson, L. , Visuri, I. , Hjortswang, H. , Udumyan, R. , Almer, S. & et al. (2018). Clinical effectiveness of golimumab: Interim analysis of the observational study of patients with ulcerative colitis on golimumab in the Swedish National Quality Registry for IBD-GO-SWIBREG. In: Journal of Crohn's & Colitis. Paper presented at 13th Congress of ECCO – European Crohn’s and Colitis Organisation, Vienna, Austria, February 14-17, 2018. (pp. S409-S410). Oxford University Press. [BibTeX]
Eriksson, C. , Rundquist, S. , Lykiardopoulos, V. , Karlen, P. , Grip, O. , Söderman, C. , Almer, S. , Hertervig, E. & et al. (2018). Clinical effectiveness of vedolizumab: Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with Crohn's disease (SVEAH CD). In: Journal of Crohn's & Colitis. Oxford University Press. [BibTeX]
Eriksson, C. , Rundquist, S. , Lykiardopoulos, V. , Karlen, P. , Grip, O. , Söderman, C. , Almer, S. , Hertervig, E. & et al. (2018). Clinical effectiveness of vedolizumab: Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with ulcerative colitis (SVEAH UC). In: Journal of Crohn's & Colitis. Oxford University Press. [BibTeX]
Eriksson, C. , Rundquist, S. , Cao, Y. , Montgomery, S. & Halfvarson, J. (2018). The impact of thiopurine drugs on the natural history and surgical outcome of ulcerative colitis: A cohort study. In: Journal of Crohn's & Colitis. Oxford University Press. [BibTeX]

Doctoral theses, comprehensive summaries

Eriksson, C. (2018). Epidemiological and therapeutic aspects of Inflammatory Bowel Disease. (Doctoral dissertation). (Comprehensive summary) Örebro: Örebro University. [BibTeX]

Manuscripts

Grännö, O. , Bergemalm, D. , Lindqvist, C. M. , Hedin, C. R. H. , Carlson, M. , Dannenberg, K. , Andersson, E. , Strid, H. & et al. A protein signature for prediction of disease course in newly diagnosed ulcerative colitis. [BibTeX]
Karlqvist, S. , Sachs, M. C. , Eriksson, C. , Cao, Y. , Montgomery, S. , Ludvigsson, J. F. , The SWIBREG Study Group, -. , Olén, O. & et al. Comparative risk of serious infection with vedolizumab vs anti-TNF in inflammatory bowel disease : results from nationwide Swedish registers. [BibTeX]
Visuri, I. , Dannenberg, K. , Salomon, B. , Ling Lundström, M. , Bergemalm, D. , Eriksson, C. , Lindqvist, C. M. , Keita, Å. V. & et al. Correlations of clinical characteristics and serum proteins with drug levels : A multicentre cohort study of patients with inflammatory bowel disease starting biologics. [BibTeX]
Wildeman, P. , Tevell, S. , Eriksson, C. , Campillay Lagos, A. , Söderquist, B. & Stenmark, B. Genomic characterization and outcome of prosthetic joint infections caused by Staphylococcus aureus. [BibTeX]
Carstens, A. , Björkqvist, O. , Lindqvist, C. M. , Rangel, I. , Repsilber, D. , Eriksson, C. , Bergemalm, D. , Bresso, F. & et al. Gut microbiota associated with treatment outcome to biological treatment in inflammatory bowel disease. [BibTeX]
Eriksson, C. , Henriksson, I. , Brus, O. , Zhulina, Y. , Nyhlin, N. , Tysk, C. & Montgomery, S. Incidence, prevalence, and clinical outcome of anaemia in inflammatory bowel disease : A population-based cohort study. [BibTeX]
Salomon, B. , Winberg, M. E. , Karlsson, M. , Lindqvist, C. M. , Grännö, O. , Eriksson, C. , Strid, H. , Öhman, L. & et al. Mucosal ACE2 protein levels, disease characteristics and fibrosisrelated proteins : A cross-sectional study of an inception cohort of patients with treatment-naïve inflammatory bowel disease. [BibTeX]
Salomon, B. , Carlson, M. , Bergemalm, D. , Andersson, E. , Hedin, C. R. , Keita, Å. V. , Carstens, A. , Grip, O. & et al. Predicting Ulcerative Colitis Course from the Mucosal Proteome : A Multicentre Inception Cohort Study with External Validation. [BibTeX]
Grännö, O. , Lindqvist, C. M. , Bergemalm, D. , Salomon, B. , Hedin, C. , Carlson, M. , Dannenberg, K. , Strid, H. & et al. The mucosa-associated gut microbiome in newly diagnosed inflammatory bowel disease. [BibTeX]
Shrestha, S. , Cao, Y. , Voghera, S. , Eriksson, C. , Schoultz, I. , Jess, T. , Ludvigsson, J. F. , Montgomery, S. & et al. The risk of extraintestinal manifestations before and after colectomy in patients with ulcerative colitis. [BibTeX]